Sanofi Receives NMPA Approval for Phase III Clinical Trial of RSV Vaccine SP0125
Sanofi (EPA: SAN), a major French multinational pharmaceutical company, has announced that it has received...
BOE-Backed Genewise Bio Secures RMB 100 Million in Series A Financing for Molecular Diagnostics
Genewise Bio, a molecular diagnostics company nurtured by BOE Technology Group, has reportedly secured RMB...
Huadong Medicine’s ROR1-Targeting ADC HDM2005 Cleared for Clinical Trials by China’s NMPA
Huadong Medicine Co., Ltd (SHE: 000963), a biopharmaceutical company based in China, has announced that...
China’s NHC Mandates Urban Hospitals to Aid County-Level Medical Institutions
The National Health Commission (NHC) has issued a notification aimed at further promoting the allocation...
Gilead and Arcus Biosciences Report Positive Combination Therapy Results in mCRC Trial
Biopharmaceutical companies Gilead (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have announced safety and efficacy...
AstraZeneca’s Tagrisso Achieves Milestone Progression-Free Survival in Late-Stage Lung Cancer Study
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has announced preliminary results from...
MicuRx Pharmaceuticals’ MRX-8 Achieves Positive Results in Phase I Clinical Study
MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has announced the successful completion...
Zhaoke Ophthalmology Partners with China’s Eye Valley to Establish Ophthalmic Research Institute
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, has announced that its subsidiary,...
Eli Lilly Acquires QurAlis’ UNC13A-Targeting Compounds for Neurodegenerative Diseases
Eli Lilly and Company (NYSE: LLY) has announced the acquisition of global development and commercialization...
Bio-Thera Solutions’ Bevacizumab Biosimilar Avzivi Recommended for Approval by EMA’s CHMP
Bio-Thera Solutions (SHA: 688177), a biopharmaceutical company based in Guangzhou, has received notification that the...
Zylox-Tonbridge Medical Technology Earns NMPA Approval for First Vascular Stapler in China
Zylox-Tonbridge Medical Technology (HKG: 2190), a leading developer of nerve and peripheral vascular interventional devices...
Akeso Expands Licensing Deal with Summit Therapeutics for Ivonescimab Bispecific Antibody
Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced a supplementary licensing...
Jiangsu Aidea Pharmaceutical Gets Green Light from NMPA for AINUOVirine APIs
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a biopharmaceutical company based in China, has announced...
China Meheco Group Appoints Yang Guang as Chairman and Legal Representative
China Meheco Group Co., Ltd (SHA: 600056) has announced the appointment of Yang Guang to...
Allergan Aesthetics’ Botox Secures New Indication for Masseter Muscle Protrusion in China
Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), has announced that it has received approval...
Legend Biotech’s Carvykti Shows Durable Responses in Multiple Myeloma Patients Post ASCT
Legend Biotech Corporation (NASDAQ: LEGN) has announced results from the Phase II CARTITUDE-2 Cohort D...
Varian Medical Gets China Approval for Fourth-Generation Halcyon Radiotherapy System
Varian Medical Systems (NYSE: VAR), a US-based leader in cancer treatment technology, has announced that...
CSPC Pharmaceutical Secures NMPA Nod for Generic Version of AstraZeneca’s Lynparza
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Akeso Biopharma’s Ivonescimab Outshines Keytruda in NSCLC Trial, Raises FDA Concerns
FiercePharma.com has reported on the reactions of multinational corporation executives to the recent news that...
Gilead and Arcus Biosciences Report Positive Interim Phase II Data for Domvanalimab Combo in GI Cancers
Gilead (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have announced interim Phase II data for...